Affinity Asset Advisors LLC Has $2.64 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Affinity Asset Advisors LLC cut its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 30.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 69,999 shares of the company’s stock after selling 30,001 shares during the quarter. Affinity Asset Advisors LLC owned about 0.09% of SpringWorks Therapeutics worth $2,637,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of SWTX. Russell Investments Group Ltd. boosted its holdings in shares of SpringWorks Therapeutics by 49.0% in the first quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock valued at $8,370,000 after buying an additional 55,893 shares during the period. Seven Eight Capital LP acquired a new position in shares of SpringWorks Therapeutics during the fourth quarter worth about $1,544,000. Price T Rowe Associates Inc. MD grew its holdings in shares of SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock worth $202,318,000 after buying an additional 1,333,892 shares in the last quarter. Perceptive Advisors LLC raised its position in SpringWorks Therapeutics by 28.7% in the 4th quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock valued at $71,439,000 after buying an additional 436,830 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in SpringWorks Therapeutics by 310.7% in the 4th quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock valued at $78,919,000 after acquiring an additional 1,635,722 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $76.00 price objective on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Wedbush reissued an “outperform” rating and set a $77.00 price target (up from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. increased their price objective on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $68.50.

SpringWorks Therapeutics Stock Down 2.2 %

NASDAQ SWTX opened at $32.15 on Wednesday. The firm’s fifty day moving average price is $37.43 and its two-hundred day moving average price is $40.97. SpringWorks Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to analyst estimates of $34.42 million. The company’s revenue for the quarter was up 59732900.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.25) earnings per share. On average, analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.